Fexofenadine hydrochloride enhances the efficacy of contact immunotherapy for extensive alopecia areata: Retrospective analysis of 121 cases

Journal of Dermatology

Volumn 36, Issue 6, 2009, Pages 323-327

  Inui, Shigeki ^a,b   Nakajima, Takeshi ^b   Toda, Naoyuki ^c   Itami, Satoshi ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c Shin Osaka Clinic   (Japan)

Author keywords

Alopecia areata; Atopy; Fexofenadine; Immunotherapy

Indexed keywords

DIPHENCYPRONE; FEXOFENADINE; SQUARIC ACID DIBUTYL ESTER;

ADOLESCENT; ADULT; AGED; ALOPECIA AREATA; ARTICLE; ATOPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HAIR GROWTH; HUMAN; IMMUNOTHERAPY; MALE; PRESCHOOL CHILD; SCHOOL CHILD; SCORING SYSTEM; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ALOPECIA AREATA; CHILD; CHILD, PRESCHOOL; CYCLOBUTANES; CYCLOPROPANES; DERMATOLOGIC AGENTS; FEMALE; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TERFENADINE; YOUNG ADULT;

EID: 66949178758     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2009.00647.x     Document Type: Article

References (25)

1. Safavi KH, Muller SA, Suman VJ et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995 70 : 628 633.
2. Gilhar A, Ullmann Y, Berkutzki T et al. Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J Clin Invest 1998 101 : 62 67. (Pubitemid 28058903)
3. Ito T, Ito N, Bettermann A et al. Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model. Am J Pathol 2004 164 : 623 634. (Pubitemid 38364677)
4. Toyoda M, Makino T, Kagoura M et al. Expression of neuropeptide-degrading enzymes in alopecia areata: an immunohistochemical study. Br J Dermatol 2001 144 : 46 54. (Pubitemid 32154592)
5. Giustizieri ML, Albanesi C, Fluhr J et al. H1 histamine receptor mediates inflammatory responses in human keratinocytes. J Allergy Clin Immunol 2004 114 : 1176 1182. (Pubitemid 39469162)
6. Ogawa H, Imai R, Nishiyama S et al. The effect of an anti-allergic drug on the disease activity of alopecia areata. Skin Res 1994 36 : 60 68. (Pubitemid 24097127)
7. Ogawa H, Ueki R, Nishiyama S et al. The effect of an anti-allergic drug (azelastine) on alopecia areata. Nishinihon J Dermatol 1995 57 : 1206 1211.
8. Yoshizawa Y, Kawana S. Efficacy of ebastine in the treatment of alopecia areata. Jpn J Dermatol 2005 115 : 1473 1480.
9. Inui S, Nakajima T, Itami S. Two cases of alopecia areata responsive to fexofenadine. J Dermatol 2007 34 : 852 854. (Pubitemid 350233355)
10. Katagiri K, Arakawa S, Hatano Y et al. Fexofenadine, an H1-receptor antagonist, partially but rapidly inhibits the itch of contact dermatitis induced by diphenylcyclopropenone in patients with alopecia areata. J Dermatol 2006 33 : 75 79. (Pubitemid 43362914)
11. Olsen E, Hordinsky M, McDonald-Hull S et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol 1999 40 : 242 246.
12. Olsen EA, Hordinsky MK, Price VH et al. Alopecia areata investigational assessment guidelines - Part II. National Alopecia Areata Foundation. J Am Acad Dermatol 2004 51 : 440 447.
13. Fiedler VC, Alaiti S. Treatment of alopecia areata. Dermatol Clin 1996 14 : 733 737.
14. Goh C, Finkel M, Christos PJ et al. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol 2006 20 : 1055 1060. (Pubitemid 44425959)
15. Ikeda T. A new classification of alopecia areata. Dermatologica 1965 131 : 421 445.
16. Katsuoka K. Atopy and alopecia areata-atopic alopecia areata MB Derma 1999 23 : 9 12.
17. Kunz B, Oranje AP, Labreze L et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997 195 : 10 19. (Pubitemid 27326702)
18. Hanifin JM, Thurston M, Omoto M et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001 10 : 11 18. (Pubitemid 32098039)
19. Kakinuma T, Nakamura K, Wakugawa M et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001 107 : 535 541. (Pubitemid 32210037)
20. Ashenager MS, Grgela T, Aragane Y et al. Inhibition of cytokine-induced expression of T-cell cytokines by antihistamines. J Investig Allergol Clin Immunol 2007 17 : 20 26. (Pubitemid 46280157)
21. Paolieri F, Battifora M, Riccio AM et al. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. Ann Allergy Asthma Immunol 1998 81 : 601 607. (Pubitemid 29036421)
22. Peters EM, Liotiri S, Bodo E et al. Probing the effects of stress mediators on the human hair follicle: substance P holds central position. Am J Pathol 2007 171 : 1872 1886.
23. Siebenhaar F, Sharov AA, Peters EM et al. Substance P as an immunomodulatory neuropeptide in a mouse model for autoimmune hair loss (alopecia areata). J Invest Dermatol 2007 127 : 1489 1497. (Pubitemid 46766534)
24. Bae S, Shimizu K, Sato S. Inhibitory effect by of fexofenadine hydrocloride on substance P-induced inflammation in the skin. Prog Med 2007 27 : 2123 2126.
25. Asano K. Inhibition by of fexofenadine hydrocloride on substance P production from dorsal root ganglion cells. Skin Allergy Frontier 2007 5 : 58 59.